Prostate cancer detection in patients with total serum prostate-specific antigen levels of 4-10 ng/mL: diagnostic efficacy of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2-weighted imaging.

OBJECTIVE The purpose of this study is to evaluate the utility of T2-weighted imaging, dynamic contrast-enhanced MRI (DCE-MRI), and diffusion-weighted imaging (DWI) for detecting prostate cancer in patients with total serum prostate-specific antigen (PSA) levels of 4-10 ng/mL, which is referred to as the "gray zone." MATERIALS AND METHODS Fifty patients with gray-zone PSA levels underwent MRI before biopsy. According to the sites of biopsy, the prostate was divided into eight regions on MRI scans. These regions were evaluated individually for the following features: detectability of prostate cancer on per-region and per-patient bases, and relationship between tumor size and positive or negative MRI findings for tumor detection. RESULTS On a per-region basis, the sensitivity and specificity of tumor detection were 36% and 97% for T2-weighted imaging, 43% and 95% for DCE-MRI, 38% and 96% for DWI, and 53% and 93% for the combined method of MRI, respectively. The sensitivity of combined MRI to detect tumor was significantly higher than those of the individual methods (p < 0.001 to p = 0.001). Tumor size was significantly larger in regions with positive MRI findings than in regions with negative MRI findings (p = 0.004). On a per-patient basis, sensitivity and specificity of combined MRI to detect prostate cancer were 83% and 80%, respectively. CONCLUSION Combined T2-weighted imaging, DWI, and DCE-MRI findings appear to be potentially useful for detecting and managing prostate cancer, even when performed for patients with gray-zone PSA levels.

[1]  P. Choyke,et al.  Prostate cancer: value of multiparametric MR imaging at 3 T for detection--histopathologic correlation. , 2010, Radiology.

[2]  Kazuro Sugimura,et al.  Prostate cancer detection with 3 T MRI: Comparison of diffusion‐weighted imaging and dynamic contrast‐enhanced MRI in combination with T2‐weighted imaging , 2010, Journal of magnetic resonance imaging : JMRI.

[3]  A. Thompson,et al.  MRI in the detection of prostate cancer: combined apparent diffusion coefficient, metabolite ratio, and vascular parameters. , 2009, AJR. American journal of roentgenology.

[4]  A. Evans,et al.  Prostate cancer detection with multi‐parametric MRI: Logistic regression analysis of quantitative T2, diffusion‐weighted imaging, and dynamic contrast‐enhanced MRI , 2009, Journal of magnetic resonance imaging : JMRI.

[5]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[6]  M. Yaffe,et al.  Intermixed normal tissue within prostate cancer: effect on MR imaging measurements of apparent diffusion coefficient and T2--sparse versus dense cancers. , 2008, Radiology.

[7]  Namkug Kim,et al.  Apparent diffusion coefficient: Prostate cancer versus noncancerous tissue according to anatomical region , 2008, Journal of magnetic resonance imaging : JMRI.

[8]  Rajeev Kumar,et al.  Potential of magnetic resonance spectroscopic imaging in predicting absence of prostate cancer in men with serum prostate-specific antigen between 4 and 10 ng/ml: a follow-up study. , 2008, Urology.

[9]  Katsuyoshi Ito,et al.  Apparent diffusion coefficient values in peripheral and transition zones of the prostate: Comparison between normal and malignant prostatic tissues and correlation with histologic grade , 2008, Journal of magnetic resonance imaging : JMRI.

[10]  Masao Fukunaga,et al.  Prostate cancer: relationships between postbiopsy hemorrhage and tumor detectability at MR diagnosis. , 2008, Radiology.

[11]  T. Shiraishi,et al.  Current trends in diagnostic and therapeutic principles for prostate cancer in Japan , 2008, International Journal of Clinical Oncology.

[12]  T. Deguchi,et al.  The potential role of prebiopsy magnetic resonance imaging combined with prostate‐specific antigen density in the detection of prostate cancer , 2008, International journal of urology : official journal of the Japanese Urological Association.

[13]  Byung Kwan Park,et al.  Value of Diffusion-Weighted Imaging for the Prediction of Prostate Cancer Location at 3T Using a Phased-Array Coil: Preliminary Results , 2007, Investigative radiology.

[14]  Masoom A Haider,et al.  Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. , 2007, AJR. American journal of roentgenology.

[15]  Thomas Hambrock,et al.  Prostate cancer: body-array versus endorectal coil MR imaging at 3 T--comparison of image quality, localization, and staging performance. , 2007, Radiology.

[16]  A. Hemal,et al.  Transrectal ultrasound‐guided biopsy of prostate voxels identified as suspicious of malignancy on three‐dimensional 1H MR spectroscopic imaging in patients with abnormal digital rectal examination or raised prostate specific antigen level of 4–10 ng/ml , 2007, NMR in biomedicine.

[17]  J. Kurhanewicz,et al.  Magnetic resonance spectroscopy in patients with locally confined prostate cancer: association of prostatic citrate and metabolic atrophy with time on hormone deprivation therapy, PSA level, and biopsy Gleason score , 2007, European Radiology.

[18]  H. Shinmoto,et al.  Prostate cancer screening: The clinical value of diffusion‐weighted imaging and dynamic MR imaging in combination with T2‐weighted imaging , 2007, Journal of magnetic resonance imaging : JMRI.

[19]  Evis Sala,et al.  Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging. , 2006, Radiology.

[20]  Y. Jo,et al.  Transperineal extended biopsy improves the clinically significant prostate cancer detection rate: A comparative study of 6 and 12 biopsy cores , 2006, International journal of urology : official journal of the Japanese Urological Association.

[21]  K. Hosseinzadeh,et al.  Endorectal diffusion‐weighted imaging in prostate cancer to differentiate malignant and benign peripheral zone tissue , 2004, Journal of magnetic resonance imaging : JMRI.

[22]  E. Crawford,et al.  Screening for prostate cancer: current recommendations. , 2004, The Urologic clinics of North America.

[23]  T. Sone,et al.  T2-weighted MR imaging of prostate cancer: multishot echo-planar imaging vs fast spin-echo imaging , 2004, European Radiology.

[24]  P. Walsh.  A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. , 2003, The Journal of urology.

[25]  P. Babb,et al.  Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part II: individual countries , 2002, BJU international.

[26]  N. Ohtake,et al.  Trends and characteristics in prostate cancer mortality in Japan , 2000, International journal of urology : official journal of the Japanese Urological Association.

[27]  A W Partin,et al.  Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. , 1998, JAMA.

[28]  J Kurhanewicz,et al.  Localizing prostate cancer in the presence of postbiopsy changes on MR images: role of proton MR spectroscopic imaging. , 1998, Radiology.

[29]  A W Partin,et al.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. , 1997, JAMA.

[30]  J. Oesterling,et al.  The effect of prostatitis, urinary retention, ejaculation, and ambulation on the serum prostate-specific antigen concentration. , 1997, The Urologic clinics of North America.

[31]  B. G. Blijenberg,et al.  The value of screening tests in the detection of prostate cancer. Part I: Results of a retrospective evaluation of 1726 men. , 1995, Urology.

[32]  C. Kim,et al.  High-b-value diffusion-weighted imaging at 3 T to detect prostate cancer: comparisons between b values of 1,000 and 2,000 s/mm2. , 2010, AJR. American journal of roentgenology.

[33]  L. Tanoue.  Cancer Statistics, 2009 , 2010 .

[34]  Kyung Ah Kim,et al.  Prostate cancer: apparent diffusion coefficient map with T2-weighted images for detection--a multireader study. , 2009, Radiology.

[35]  Namkug Kim,et al.  Functional MR imaging of prostate cancer. , 2007, Radiographics : a review publication of the Radiological Society of North America, Inc.

[36]  T. Marugame,et al.  Cancer Statistics Digest Comparison of Bladder Cancer Mortality in Five Countries : France , Italy , Japan , UK and USA from the WHO Mortality Database ( 1960 – 2000 ) , 2005 .

[37]  T. Marugame,et al.  Comparison of prostate cancer mortality in five countries: France, Italy, Japan, UK and USA from the WHO mortality database (1960-2000). , 2005, Japanese journal of clinical oncology.

[38]  B. Matlaga,et al.  Prostate biopsy: indications and technique. , 2003, The Journal of urology.

[39]  J. Vilanova,et al.  The value of endorectal MR imaging to predict positive biopsies in clinically intermediate-risk prostate cancer patients , 2001, European Radiology.